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Key point summary:  
• For therapeutic antibodies, frequently, total tissue concentrations are reported 
representing a lump sum measure of antibody in residual plasma, interstitial fluid and 
cells. In terms of correlating antibody exposure to a therapeutic effect, however, 
interstitial pharmacokinetics might be most relevant. 
• In this work we collected total tissue and interstitial antibody biodistribution data in mice 
and assessed the composition of tissue samples in order to correct total tissue 
measurements for plasma- and cellular content. 




pharmacokinetic (PBPK) model for monoclonal antibodies in order to allow for a tissue 
specific description of antibody pharmacokinetics in the interstitial space. 
• We found that antibody interstitial concentrations are highly tissue-specific and 
dependent on the underlying capillary structure but in several tissues reach relatively high 
interstitial concentrations contradicting the still-prevailing view that distribution to 
tissues and interstitial concentrations for antibodies are generally low. 
 
Abstract 
For most therapeutic antibodies, the interstitium is the target space. Although experimental 
methods for measuring antibody pharmacokinetics (PK) in this space are not well established, 
making quantitative assessment difficult, the interstitial antibody concentration is assumed to be 
low. Here, we combined direct quantification of antibodies in the interstitial fluid with a 
physiologically-based PK (PBPK) modelling approach with the goal of better describing the PK 
of monoclonal antibodies in the interstitial space of different tissues. We isolated interstitial fluid 
by tissue centrifugation, and conducted an antibody biodistribution study in mice, measuring 
total tissue- and interstitial concentrations in selected tissues. Residual plasma, interstitial 
volumes and lymph flows, which are important PBPK model parameters, were assessed in vivo. 
We could thereby refine PBPK modelling of monoclonal antibodies, better interpret antibody 
biodistribution data and more accurately predict their PK in the different tissue spaces. Our 
results indicate that in tissues with discontinuous capillaries (liver and spleen), interstitial 
concentrations are reflected by plasma concentration. In tissues with continuous capillaries (e.g. 
skin and muscle), ~50-60% of plasma concentration is found in the interstitial space. In brain and 
kidney, on the other hand, antibodies are restricted to the vascular space. Our data may 
significantly impact the interpretation of biodistribution data of monoclonal antibodies and might 
be important when relating measured concentrations to a therapeutic effect. Opposing the view 
that antibodies distribution to the interstitial space is limited, we show by direct measurements 





Abbreviations: BSA, bovine serum albumin; Cev, extravascular concentration; Cmax, maximal 
concentration; CO, cardiac output; Cpla, plasma concentration;  Ctis, total tissue concentration; 
fVectis, tissue extracellular volume fraction; fVinttis, tissue interstitial volume fraction; 
fVresplatis, tissue residual plasma volume fraction;  EDTA, ethylenediaminetetraacetic acid; 
FcRn, neonatal Fc receptor; HSA, human serum albumin; IL17, interleukin 17; Ltis, tissue lymph 
flow;  PBPK, physiologically based pharmacokinetic; PK, pharmacokinetics; PKPD, 
pharmacokinetic/pharmacodynamic;  
Introduction 
The importance of therapeutic antibodies in drug therapy has steadily increased over recent 
years. The pharmacokinetics (PK) of large molecules differs in many aspects from small 
molecule drugs as discussed in several recent reviews (Jones et al., 2013; Ferl et al., 2016; Wan, 
2016). Nonetheless, distribution of antibodies in the sub-compartments (vascular, interstitial and 
cellular space) of different tissues is still not well-established in quantitative terms because 
experimental measurements at the sub-compartmental level of tissues are challenging. Therefore, 
most PK data for large molecules are reported as total tissue concentrations, however, this may 
not represent the effects driving concentration, but rather a mixture of vascular, intracellular and 
interstitial concentrations (Danhof et al., 2007; Mouton et al., 2008; Mariappan et al., 2013). 
Notable differences in concentration levels are expected between the tissue sub-compartments 
(Lobo et al., 2004; Wang et al., 2008). Many therapeutic antibodies bind to targets on the cell 
surface and thus induce their therapeutic effect within the interstitial space of a tissue (i.e. the 
biophase) (Boswell et al., 2012). Therefore accurate measurements or predictions of tissue 
interstitial concentrations are critical in order to estimate how much of the drug reaches the 
therapeutic target and evaluate the PKPD properties of therapeutic antibodies during drug 
development (Danhof et al., 2007; Mariappan et al., 2013). 
So far, there is no broadly accepted gold standard method to experimentally assess antibody 
concentration in the interstitial space, i.e., at the target site (Wiig & Swartz, 2012). If total tissue 
concentrations are measured by ELISA or radiolabelling, subsequent corrections for residual 
plasma contamination and interstitial volume fractions of the underlying tissue might be applied 




2007; Fronton et al., 2014). Alternatively, PBPK models provide a robust tool for predicting the 
PK in the different tissue sub-compartments and can be further used to evaluate PK properties of 
compounds in development and to scale between different species or patient populations. They 
mathematically describe distribution of compounds throughout the body based on physiological 
processes, anatomical structures and physicochemical drug properties. Yet, because of the lack 
of physiological and quantitative knowledge surrounding driving processes for the 
biodistribution of large molecules, these models still contain a number of unknown physiological 
parameters which are required as inputs. This is also reflected by the diverse structure and 
parameterization of already published large molecule PBPK models (Covell et al., 1986; Baxter 
et al., 1994; Ferl et al., 2005; Garg & Balthasar, 2007; Davda et al., 2008; Urva et al., 2010; 
Chen & Balthasar, 2012; Shah & Betts, 2012; Jones et al., 2013; Fronton et al., 2014). Further 
development and validation of large molecule PBPK models therefore require additional 
research to inform understanding of underlying distribution processes.   
In this work, our objective was to investigate the PK of monoclonal antibodies in the interstitial 
space of individual tissues. Such knowledge would allow us to answer the question of how much 
of the administered therapeutic dose will reach the target site in a specific tissue. We herein 
report new biodistribution data, including measured interstitial concentrations in selected tissues, 
and parameter values forming the basis of a PBPK modelling approach, thereby providing new 
knowledge on tissue distribution and effect-driving concentrations of monoclonal antibodies. 
Our new findings are integrated into a PBPK model framework, enabling us to make antibody 
PK predictions at the target site in different tissues. Our data suggest high antibody exposure in 
the interstitial space of most organs, except the brain and kidney, and we show that often 
reported total tissue concentrations are much lower for many tissues than their interstitial 
concentrations. We demonstrate that an accurate assessment and interpretation of correction 
factors and input parameters are pivotal for the assessment of antibody PK. Importantly, our 
results clearly indicate that high interstitial concentrations can be achieved for antibodies in most 
tissues, which contradicts the prevalent assumption that therapeutic antibody concentrations in 




Materials & Methods 
Ethical approval  
All in vivo studies were carried out in accordance with the regulations of the Norwegian State 
Commission for Laboratory Animals in agreement with the European Convention for the 
Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes and 
Council of Europe (ETS 123) and approved by the AAALAC International Accredited Animal 
Care and Use Program at University of Bergen. The authors also confirm to be compliant with 
the ethical principles under which The Journal of Physiology operates and to adhere to the 
Animal Ethics Checklist presented in the editorial by Grundy (Grundy, 2015). 
Animal studies 
FVB/NhanHsd mice supplied by Envigo (An Venray, Netherlands) were used for all in vivo 
measurements. For every study, both sexes were used (total of 34 females and 26 males). The 
body weights ranged from 19-34 g with a mean of 23 g and the age of the animals ranging from 
8-12 weeks. The mice were fed ad libitum. During invasive experimental procedures, the animals 
were anesthetized with 1.5% isoflurane (IsoFlo®Vet 100%, ABBOTT Laboratories Ltd, 
England) in 100% O2. The depth of anaesthesia was monitored by testing the withdrawal reflexes 
(paw). During anaesthesia, the body temperature was kept stable using a servo-controlled heating 
pad and rectal probe. At the end of the experiment, animals were euthanized by cervical 
dislocation. 
Radiolabelled probes 
We used various radiolabelled compounds in our in vivo studies. 51Cr-ethylenediaminetetraacetic 
acid (EDTA) (produced by GE Healthcare Limited, delivered by IFE, Institute for Energy 
Technology, Norway) was utilised for assessment of extracellular spaces. Human serum albumin 
(HSA) and anti-interleukin 17 (IL17) IgG were labelled with 125-iodine using Iodo-Gen as 
described in detail previously (Wiig et al., 2005). In summary, a solution of 5 mg 1,3,4,6-
tetrachloro-3α,6α-diphenylglycouril (Sigma-Aldrich Co., product number T0656) in 5 mL 




Roskilde, Denmark). Chloroform was evaporated under nitrogen forming water-insoluble Iodo-
Gen in the Nunc vial. One and a half mg of compound was added to 1 mL 0.05 M PBS with15 
µL 0.01 M NaI and 10 MBq 125I (Institute for Energy Technology, Kjeller, Norway). The vial 
was gently mixed for 10 min before the solution was removed. The tracer solution was dialysed 
against 1 L of 0.9% of saline and 0.02% azide to remove unincorporated isotope. The labelled 
probes were additionally purified prior to each intravenous injection using a 40 kDa cut-off spin 
filter (Amicon). Separate terminal plasma and urine samples were collected during the study and 
tested for free iodine and purity using spin filters and high-through put liquid chromatography 
(HPLC). 
Biodistribution study 
Concentrations of 125anti-IL17 IgG were measured in plasma and 11 tissues (adipose, bone, 
brain, gut, heart, kidney, liver, lung, muscle, skin and spleen) at 10 time points with three mice at 
each time point. Sampling times were 10, 30 and 90 min, 3, 6 and 12 h and 1, 2, 5 and 15 d, with 
the focus being on early time points in order to resolve the early tissue distribution phase. A dose 
of 10 mg/kg was administered i.v. through the tail vein. For terminal tissue sampling, mice were 
anaesthetized; a blood sample was retrieved from the tail vein using heparinized glass capillaries 
followed by euthanasia. Plasma was isolated by centrifugation of the blood sample for 10 min at 
1000 g. Harvested tissue samples were blotted dry on a paper tissue to remove surface blood. 
Separate samples for skin and muscle were obtained in order to isolate interstitial fluid by tissue 
centrifugation. Samples were weighed, transferred to vials and radioactivity was determined in a 
gamma-counting system (Wallac Wizard 1470 gamma counter, PerkinElmer). An additional 
blood sample was taken at several time points and filtered through a spin filter (40 kDa cut off) 
in order to determine the amount of free iodine in the system. The amount of drug was assessed 
based on specific activity of the probe and correction for radioactive decay. Drug content in 
tissues is reported per gram wet weight of the respective tissue. The tissue sample volumes (Vtis) 








A density of 1 g/cm3 was assumed for all tissues, except 0.92 and 1.3 g/cm3 for adipose and 




A preliminary study was performed to test the isolation of native interstitial fluid using the tissue 
centrifugation technique (Wiig et al., 2003) from 11 tissues (adipose, bone, brain, gut, heart, 
kidney, liver, lung, muscle, skin and spleen) and evaluate the plasma admixture and dilution by 
intracellular fluid in the centrifugate of each tissue. Based on the obtained data, muscle and skin 
were selected to establish interstitial PK during the biodistribution study as these tissues allowed 
collection of relatively pure interstitial fluid with limited plasma and intracellular fluid 
contamination. To avoid evaporation, all procedures were performed in a humidity chamber 
(98% relative humidity). Tissue samples were placed on a mesh in an Eppendorf tube and 
centrifuged at low speed of 424 g for 10 min. After centrifugation, the tubes were immediately 
transferred back to the humidity chamber where isolated fluid samples at the bottom of the tube 
were transferred into a tube containing 500 μL of saline and counted in the gamma counter to 
measure the 125anti-IL17 IgG content in the centrifugate.  
Tissue volume fractions 
Extracellular space by 51Cr-EDTA 
The time needed for tracer equilibration was tested in preliminary studies. Under anaesthesia, 
two 1 cm incisions penetrating the skin and muscle layer were made lateral from the spine and 
below the rib cage, and the kidney pedicles were tied off to prevent tracer excretion. Following 
wound closure, 51Cr-EDTA (~16.6 kBq in 100 μL) was injected i.v. into the tail vein of seven 
mice. Serial blood sampling from the tail vein after 30, 60 and 90 min revealed that tracer levels 
in plasma were not different at these time points. Although this suggests that the tracer was 
equilibrated already at 30 min, we chose the 60 min equilibration time for the extracellular tracer 




before. The mice were kept under anaesthesia for 60 minutes before a terminal blood sample was 
withdrawn and the animals were euthanized. Subsequently, adipose tissue, bone, brain, gut, 
heart, kidney, liver, lung, muscle, skin and spleen were harvested. Surface blood was removed by 
briefly blotting tissues on a paper tissue. All samples were weighed, transferred to counting tubes 
and counted in the gamma counter. The tissue extracellular volume fraction (fVectis) was 
calculated as:  
𝑓𝑉𝑒𝑐𝑡𝑖𝑠 =
𝐶𝑟 𝑐𝑜𝑢𝑛𝑡𝑠51 𝑔 𝑡𝑖𝑠𝑠𝑢𝑒⁄
𝐶𝑟 𝑐𝑜𝑢𝑛𝑡𝑠51 𝑚𝐿 𝑝𝑙𝑎𝑠𝑚𝑎⁄
         (2) 
   
Residual plasma space by 125I-HSA 
After anaesthesia, six mice received an i.v. bolus injection of 125I-HSA (~17 kBq in 100 μL) that 
was allowed for a 5 min distribution time, sufficient to distribute in but not to extravasate from 
plasma (with few exceptions, as described in what follows) before blood sampling and 
euthanasia. Thereafter, tissues were harvested, blotted dry and transferred to the gamma counter. 
Importantly, no other measures to remove additional blood were employed. Residual plasma 
fractions (fVresplatis) in harvested tissues were calculated as follows: 
𝑓𝑉𝑟𝑒𝑠𝑝𝑙𝑎𝑡𝑖𝑠 =
𝐼 𝑐𝑜𝑢𝑛𝑡𝑠125 𝑔 𝑡𝑖𝑠𝑠𝑢𝑒⁄
𝐼 𝑐𝑜𝑢𝑛𝑡𝑠125 𝑚𝐿 𝑝𝑙𝑎𝑠𝑚𝑎⁄
         (3) 
Interstitial volume fractions 
We used our measured volume fractions to derive a tissue interstitial volume fraction (fVinttis) 
based on the following relationship: 
𝑓𝑉𝑖𝑛𝑡𝑡𝑖𝑠 = 𝑓𝑉𝑒𝑐𝑡𝑖𝑠 − 𝑓𝑉𝑟𝑒𝑠𝑝𝑙𝑎𝑡𝑖𝑠         (4) 
Lymph flow measurements 
To measure the lymph flow in muscle and skin, Alexa 680-labelled macromolecular tracers were 
injected intradermally and intramuscularly in the hind paw and thigh of mice respectively. 
Washout rates of the tracer from the injection site were assessed by optical imaging using the 




monoexponential reduction of the fluorescent signal as described in detail previously (Karlsen et 
al., 2012). In short, we fluorescently labelled bovine serum albumin (BSA), anti-IL17 IgG 
antibody and a Triple-A mutant (neonatal Fc receptor (FcRn) non-binding) antibody with the 
near infrared Alexa680 fluorophore with an antibody labelling kit (SAVITM Rapid Antibody 
Labelling Kit, Invitrogen). The three different macromolecular tracers were employed to check 
for a possible effect of molecular weight (BSA vs. anti-IL17 IgG) and FcRn binding (anti-IL17 
IgG vs. FcRn non-binding IgG) upon removal from the interstitial space. Volumes of 0.5 μL of 
tracer were injected with a 34G Hamilton syringe. After a 60 min distribution phase, five 
measurements were taken with 1 h intervals. Animals were anesthetized during imaging, but 
awake and freely moving in between the measurements to assess washout of normally active 
animals, knowing that immobility reduces lymph flow (Lindena et al., 1986; Modi et al., 2007). 
For each tracer and tissue the washout was assessed in six individuals. Optix Optiview software 
was used to analyse the images. Flow values were subsequently derived by multiplying removal 
rates from the interstitial volume of the respective tissue: 
 𝐿𝑡𝑖𝑠 =  𝑓𝑉𝑖𝑛𝑡𝑡𝑖𝑠 ×  𝑉𝑡𝑖𝑠 ×  𝑘,          (5) 
where Ltis it the tissue lymph flow, fVint the interstitial volume fraction, Vtis the tissue volume 
and k the measured tracer removal rate. 
Corrections of total tissue concentrations 
During the biodistribution experiments, plasma and total tissue concentrations were measured. 
Extravascular tissue concentrations were derived by subtracting the amount of antibody in the 
residual plasma from the measured total amount found in tissue and dividing what remained by 
the extravascular tissue volume (Garg, 2007; Fronton et al., 2014): 
𝐶𝑒𝑣 =  
𝐶𝑡𝑖𝑠×𝑉𝑡𝑖𝑠−𝐶𝑝𝑙𝑎×𝑉𝑟𝑒𝑠𝑝𝑙𝑎𝑡𝑖𝑠
𝑉𝑡𝑖𝑠−𝑉𝑟𝑒𝑠𝑝𝑙𝑎𝑡𝑖𝑠
         (6) 
Cev represents the tissue extravascular concentration, Ctis the experimentally assessed total tissue 
concentration, Cpla the plasma concentration and Vtis the experimentally measured total tissue 




determined based on the corresponding measured residual plasma fraction multiplied with the 
total sample volume. Residual plasma fractions utilised for correction were based on the 125I-
HSA distribution. Under the same assumptions, we additionally used the measured amount of 
anti-IL17 IgG in tissues after 10 min in the biodistribution study for residual plasma corrections. 
Statistics 
Mean and standard deviation (SD) are reported for measured data. For comparison of groups a 
two-tailed Student’s t-test or one-way analysis of variance (ANOVA) was conducted. P ≤0.05 
was considered statistically significant. Analyses were performed in GraphPad PRISM version 
6.0. 
PBPK modelling  
We integrated and evaluated the newly measured biodistribution data and parameter values in a 
PBPK modelling approach. The model was coded in the Simbiology toolbox in MATLAB 
R2016a and was used to fit total tissue- and, where available, interstitial concentrations. Tissue 
distribution , lymph flows (except for the muscle and skin), systemic plasma volume, systemic 
clearance and interstitial accessible volume for the skin and muscle were estimated using the 
fminsearchbound and lsqnonlin algorithms, whereas other parameters were fixed to reported 
values (Shah & Betts, 2012). The herein measured physiological parameter values (i.e. residual 
plasma- and interstitial volume fractions and lymph flow in the skin and muscle) were utilised as 
input parameters for the model and limited to a range of measured values ± 20% during the 
estimation to permit variability. The presented model integrated only well-established or required 
parameters and mechanisms in order to describe our data and allow prediction of the 
concentrations in the different tissue sub-compartments. For this analysis we avoided, wherever 
possible, including parts into the model structure where no experimental data were available and 
which were not directly affecting our research question (e.g., detailed endosomal compartment, 
FcRn receptor, target binding, etc.). Furthermore, as all major organs were sampled and included 
within the model structure, making up for 92% of the body weight and 95% of the cardiac 
output. Therefore, no additional carcass or rest of body compartment was included. This is not 





Tissue distribution space, inflow and removal of antibodies were modelled differently for the 
individual tissues based on their capillary structure. Tissues with continuous capillaries provide a 
distinct separation of vascular and interstitial space for macromolecules. Therefore, tissue 
distribution, representing a lump sum of convective flow and reflection coefficient, and removal 
(i.e., lymph flow) was estimated. Tissues with especially tight and size-selective capillaries 
(blood brain barrier and glomerular filter of the kidneys) were modelled solely by the vascular 
space because macromolecules are assumed to be restricted here and the measured amount in 
tissue is entirely explained by the extent of the residual plasma content. Thus, no distribution to 
the interstitial space or lymph removal was accounted for with these tissues. In the case of tissues 
with discontinuous capillaries, the vessel wall does not provide a clear separation of vascular and 
interstitial space for IgGs and the two spaces equilibrate rapidly, therefore interstitial 
concentration is assumed to reach plasma concentration levels within a few minutes. As such, in 
these tissues the distribution space was modelled as one lumped space containing the vascular 
and interstitial compartment. Antibody drugs enter this space by arterial blood flow and are 
removed by venous blood- and lymph flow that can, however, not be distinguished based on the 
data. An exclusion volume in the interstitial space of the skin and muscle was estimated based on 
the measured interstitial volumes and PK data. Tissue-intrinsic clearances were integrated based 
on previously published contribution of tissue clearances to the total plasma clearance 
(Eigenmann et al., 2017). A schematic representation of the model is found in Figure 1 and the 
model equations are presented in the Appendix. After fitting the PBPK model to the 
biodistribution data and parameter estimation, the model was utilised in order to simulate the PK 
in the tissue sub-compartments of the individual tissues. The PBPK model source code 
(Simbiology file) and a MATLAB-script which enable running and plotting the simulations 
based on the model and parameter values we present in this work was provided as supportive 
information. 
Results 
Antibody biodistribution study 




study in normal FvB mice. The biodistribution data, including plasma and tissue PK profiles are 
presented in Figure 2. The measured concentrations represent total tissue concentrations. After 
an i.v. dose of 10mg/kg, a plasma PK biphasic profile was observed. Maximal concentration 
(Cmax) was 215ug/mL followed by a fast decline in concentration, which indicated the tissue 
distribution phase. Total tissue concentrations were mostly >1 order of magnitude lower than the 
plasma concentration. Well-perfused organs like the heart, kidney, liver, lung and spleen had 
generally higher total concentrations, while lower concentrations were determined in adipose, 
bone and muscle. Over the time course of the entire study, negligible free iodine was measured 
(<0.4%) within the system. 
Tissue centrifugation – interstitial concentrations 
In order to measure interstitial concentrations in the skin and muscle and compare them to the 
respective total tissue PK we isolated native interstitial fluid from the muscle and skin by tissue 
centrifugation and directly assessed anti-IL17 IgG interstitial concentrations.  In the centrifugate 
the plasma content and intracellular dilution was assessed by 125I-albumin and 51Cr-EDTA 
centrifugate-to-plasma ratios. Residual plasma fraction of 0.065 and 0.056 were measured in the 
centrifugate for skin and muscle respectively. 51Cr-EDTA tissue-to-plasma ratios of ~1.12 and 
~0.79 were found for the skin and muscle, respectively, indicating slight contamination by 
intracellular fluid in the muscle centrifugate. The biodistribution data in the centrifugate were 
corrected for these factors. The interstitial PK profiles for both tissues are depicted in Figure 3. 
In each, a Cmax of about 45 ug/mL was observed corresponding to ~50% of the plasma 
concentration after reaching Cmax. This indicates high interstitial exposure for antibodies in the 
skin and muscle. Compared to the measured, corresponding total tissue concentrations, the 
interstitial concentration is >10 times or >3 times higher for muscle and skin, respectively. 
Tissue volume fractions 
In a next step, we assessed residual plasma and interstitial fluid per gram of tissue to attribute the 
total amount of measured drug in the tissue sample to the various tissue sub-compartments. 
Residual plasma and extracellular volumes were established by tracer distribution, whereas 




extracellular space.  These volume fractions are important input parameters in the PBPK model 
and are necessary to more accurately describe distribution to and within the individual tissues. 
Extracellular tissue volumes were assessed using a 51Cr-EDTA tracer and measuring its 
distribution volumes in tissues 60 min after injection. Extracellular volumes were derived for all 
tissues and individual volumes, mean and standard deviation are located in Figure 4a. The 
highest mean extracellular volume fraction of 0.45 was found for the skin. No measurements are 
available for brain (blood brain barrier) and kidneys (tied off because of excretion). Residual 
plasma fractions assessed from the 5 min distribution space of 125I-HSA are summarized in 
Figure 4b. High residual plasma volumes were found for the lung, kidney, liver, heart and spleen, 
whereas they were lower in the bone, gut, skin brain, muscle and adipose. It is of note, however, 
that in tissues with leaky, discontinuous capillaries (i.e., liver, spleen and bone marrow), tracer 
likely extravasated, therefore resulting in an overestimation of the local plasma volume.    
We calculated the interstitial space volume in tissues by subtracting the residual plasma from the 
extracellular fluid fraction. As evident from Table 1, the skin interstitial volume fraction of 0.431 
was by far the highest. In contrast, the lowest interstitial volume fraction of 0.093 was found in 
adipose tissue. In other tissues, corresponding volume fractions were in the range of 0.12 – 0.24. 
Overall, the fractional volumes (extracellular, residual plasma and interstitial) could be measured 
with strong precision. Exceptionally, adipose tissue had a rather high coefficient of variation 
(42.9-47.8 %). All volume fractions and coefficients of variation are summarized in Table 1. 
Corrections of total tissue concentrations 
Extravascular tissue concentrations derived by subtracting the amount of antibody in the residual 
plasma from the total tissue concentrations are reported in Figures 5 and 6. Therein, the impact is 
portrayed in terms of residual plasma contamination in the different tissues on the measured 
antibody content in total tissue samples and the importance of accounting for it when interpreting 
total tissue measurements. The blue shaded areas are derivative of correcting for residual plasma 
fractions as measured based on tissue distribution of labelled HSA and anti-IL17 IgG after 5 and 
10 min of distribution time, respectively. As evident from Figure 5, there was a more profound 




versus the lesser perfused adipose, gut, muscle and skin. 
The same correction approach was applied for bone, brain, kidney, liver and spleen (Figure 6), 
though it is seen that in these tissues, the entire amount of the drug appears to be in the measured 
125I-albumin- or very early anti-IL17 IgG distribution spaces. After subtraction of the amount of 
drug within these spaces, the anticipated concentration range approximates towards zero.  
Lymph flow in muscle and skin 
Lymph flow is a critical parameter for antibody biodistribution because it represents the exit 
route for macromolecules from the interstitial space back to the plasma. This parameter was 
assessed in muscle and skin based on near-infrared labelled BSA, anti-IL17 IgG and FcRn non-
binding IgG. We investigated whether there was an influence of molecular size, between 66.4 
kDa and 150 kDa, and of FcRn binding on the macromolecular washout from the tissue 
interstitial space. A size-dependent hindrance in accessing lymph vessels would appear as a 
faster removal rate for labelled BSA compared with IgG antibody. If FcRn-based transcytosis 
were an alternative means for antibodies to leave the tissue interstitial space, the FcRn non-
binding antibody would have a lower washout rate than anti-IL17 IgG with normal FcRn 
binding. The measured removal rates for skin and muscle for the three macromolecules are 
presented in Figure 7. 
No statistically significant differences in washout of the three different tracers were found using 
one-way ANOVA (p-values of 0.5 and 0.6 for skin and muscle respectively), indicating no 
influence of molecular weight and FcRn-based transcytosis on the measured removal rate. The 
actual flow values were determined by multiplying the mean removal rates (Figure 7) with the 
interstitial tissue volume (Table 2) that was assessed earlier in this work in accordance with 
equation 5. The lymph flow derived for skin was 0.633±0.134 mL/h, and for muscle, it was 
0.162±0.052 mL/h. 
PBPK modelling  
The available data and parameter values were integrated into the PBPK model and PK in the 




biodistribution parameters for monoclonal antibodies and the model could subsequently be used 
for predictions of antibody PK in different tissue sub-compartments following alternative dosing 
schedules, with potential value as a tool for translation to other species. The final model fostered 
a good description of the biodistribution data and PK in the different tissue sub-compartments 
(interstitial and vascular). Model parameters were precisely estimated. The parameter values in 
the final model are displayed in Table 2.  
Model fits and the prediction of drug content per gram of tissue in the various tissue sub-
compartments for all analysed tissues are depicted in Figure 8. For tissues with discontinuous 
capillaries (liver and spleen), the vascular and interstitial space cannot be discriminated as a 
consequence of the quick exchange in these spaces. Interstitial concentrations are expected to 
follow that of plasma. In tissues with very tight or size-selective capillaries (blood brain barrier, 
glomerular filter of the kidneys), antibodies are expected to be restricted to the vascular space 
and no or negligible interstitial concentrations are predicted. In these cases, lymph flow and 
distribution to the tissue interstitial space cannot be determined using model estimation, and the 
measured interstitial volume fraction not be employed as an input value. The interstitial 
concentrations measured in the skin and muscle were well-described by the model featuring an 
estimated interstitial exclusion of 37% and 25%, respectively.   
The sensitivity of simulated PK profiles on perturbations on individual parameters was 
evaluated. Changes in tissue-specific parameters did not significantly affect the PK in different 
tissues. Altering the systemic plasma clearance had a great impact on the elimination phase for 
all tissues. In the liver, spleen, brain and kidney varying the vascular or lumped 
vascular/interstitial volume fractions strongly affected the level of the simulated PK profile. In 
tissues with continuous capillaries, parameter sensitivity was high for interstitial and vascular 
volume fractions, thereby modifying the concentration level. Altering the lymph flow and tissue 
distribution flow in these tissues, on the other hand, notably affected the concentration level 
while also having an effect on the kinetics (i.e., time when maximal concentration is observed). 
Generally insignificant sensitivity was observed for tissue plasma flows. The calculated 
sensitivities for each parameter, averaged over the simulated time-course, are summarized in a 





In this work, we investigated determinants of tissue distribution and biophase concentrations of 
therapeutic antibodies in different tissues using: (i) tissue centrifugation to directly assess 
interstitial concentrations; and (ii) correction of total tissue concentrations and the related impact 
on PBPK modelling. Also, early time points (i.e., 10, 30 and 90 min) were sampled during the 
antibody biodistribution study, in order to garner insights into tissue distribution within the 
individual tissues.  
In terms of total tissue concentrations, our results are in strong agreement with previous 
published antibody biodistribution studies, which can be seen first-hand when comparing the 
antibody biodistribution coefficients with those compiled by Shah et al. (Shah & Betts, 2013). 
Additionally, base distribution parameters, volume of distribution (1.25 mL) and systemic 
clearance (8.6 mL/d/kg), were all within the expected range (Deng et al., 2011). Important 
differences are notable, however, when reviewing the expected extravascular and interstitial 
concentrations. Here, we showed high interstitial antibody exposure to target cells in muscle and 
skin with concentrations up to 50% of the plasma concentration. For large molecules, corrections 
for drug in residual plasma are frequently performed in order to calculate extravascular 
concentrations. Interestingly, these corrections, with residual plasma of the respective tissues 
measured by 125I-HSA and 125anti-IL17 IgG distribution space, resulted in negligible anticipated 
extravascular concentrations in brain and kidney. This is probably explained by the very tight 
capillaries constituting the blood brain barrier and the size-selective fenestrated capillaries in the 
glomerular filter. Both types of capillaries practically prevent IgG antibodies from entering the 
tissue space. Further, with regards to the liver, spleen and bone, the zero line was included after 
correcting for the amount of drug in the distribution space of the macromolecular tracer. For 
these tissues, however, the interpretation of this finding would be the opposite. These tissues 
possess discontinuous capillary walls that are non-restrictive to proteins (Rippe & Haraldsson, 
1994; Sarin, 2010). Therefore, the measured space with the macromolecular tracer used for 
correction most probably represents a mix of the plasma and interstitial space. Correcting for the 
amount of drug in that space should therefore not be performed to calculate extravascular 




organs at between 5 to 10 min of circulation time. As a result of this facilitated exchange with 
the plasma space, the extravascular space of tissues, with discontinuous capillaries, might be 
interpreted as extended plasma spaces. This finding leads to the assumption that interstitial 
concentrations in tissue with discontinuous capillaries are reflected by the plasma concentration. 
Overall, our results provide evidence that total tissue concentrations are much lower than the 
actual interstitial concentrations in tissues (except in the brain and kidneys). Therefore, our 
findings contrast with the common notion in the pharmacological literature that interstitial 
concentrations are generally much lower than vascular concentrations (Lobo et al., 2004; Wang 
et al., 2008). On the other hand, they are in line with earlier published pre-nodal lymph to plasma 
concentration ratios of macromolecules in various tissues (e.g., (Aukland & Reed, 1993; Michel 
& Curry, 1999), where pre-nodal lymph can be expected to be representative for interstitial fluid 
in steady state conditions.  
Distribution spaces for 125I-HSA- and chromium EDTA were measured with robust precision. 
The residual plasma fractions based on HSA distribution were systematically higher than 
previously reported (Garg, 2007; Boswell et al., 2014). These previous values are based on the 
distribution of red blood cells. In such cases, a systemic haematocrit value is regularly employed 
used to derive the residual plasma volumes in tissues. Yet, it is well-established that the local 
haematocrit in the smaller tissue vessels might be considerably lower than the systemic 
haematocrit, known as the “Fåhræus Lindqvist effect” or the “screening effect” (Goldsmith et al., 
1989; Fung, 1993). Therefore, utilising systemic haematocrit values to derive residual plasma 
fractions based on red blood cell fractions will erroneously lead to lower correction factors, 
thereby introducing a systematic bias. The quantitative importance of such bias is illustrated in 
Figure 10, where there is the comparison of the PK profiles for the analysed tissues, including 
residual plasma corrections based on red blood cell distribution (Garg, 2007; Boswell et al., 
2014) and based on 125I-HSA and 125anti-IL17 IgG distribution after 5 and 10 min of circulation 
time, respectively. A direct assessment of the plasma space is hence, in our opinion more 
representative with the exception of organs with discontinuous capillaries, where the tracer will 
quickly extravasate and equilibrate in the entire extravascular phase as discussed earlier. 




with previous literature (Pierson et al., 1978; Tsuji et al., 1983; Boswell et al., 2014), especially 
considering the different properties of the applied tracers. These findings show that corrective 
factors have a major impact on estimated extravascular concentration, thus demonstrating the 
significance of exact measurements as possible and careful interpretation of the results. A critical 
evaluation of the used tracer is therefore warranted with such values as fixed input parameters in 
a PBPK model. 
Lymph flow plays an important role in the biodistribution of therapeutic antibodies because of its 
involvement in the transport of filtered macromolecules from the interstitium back to the 
systemic blood circulation (Wiig & Swartz, 2012). As such, it is a critical parameter in most 
large molecule PBPK models. However, the input values used for tissue lymph flow in different 
published PBPK models vary by a factor of up to ~5000 times and no systematic measurement 
values are available (Ferl et al., 2005; Fronton et al., 2014). Here, we derived tissue lymph flow 
values in the muscle and skin based on macromolecular washout in order to directly use 
measured values in PBPK models. Integration of both measured lymph flow values result in an 
adequate description of the biodistribution data. Optimized lymph flow values by model-based 
parameter estimation would, however, be lower in the skin (0.15 vs. 0.47 mL/h) and slightly 
lower in muscle (0.10 vs. 0.12 mL/h). Nevertheless, the measured lymph flows serves as reliable 
input values for the PBPK model and foster critical evaluation of previously used values. This 
also suggests that flow is highly tissue-specific and might not be well-captured by fixing it to a 
given fraction of the respective plasma flow for all tissues. The lymph flow values we employed 
here based on our in vivo washout assessment correspond to 1.9% and 0.17% of the plasma flow 
(Table 2) in the skin and muscle, respectively. 
The PBPK modelling approach showed that for tissues with very limited or very quick 
extravasation, estimation of parameters for antibody distribution to or removal from the 
interstitial space is not feasible based on the biodistribution data, despite extensive and early 
sampling times. The model structure did therefore not include distribution to and removal from 
the interstitial space for these tissues either antibody distribution was restricted to the vascular 
space in the case of very tight capillary structures or the plasma and interstitial space were 




tissues with discontinuous capillaries, the biophase concentration would hence follow the plasma 
concentration levels. The amount of drug measured in the brain and kidney was explainable 
solely by the expected drug in the residual plasma of these tissues.  It should be noted, though, 
that if corrective factors for residual plasma are fixed values that are too low, the model would be 
forced to describe the remaining unexplained antibody content by estimation of distribution to 
and removal from the interstitial space. For tissues with continuous capillaries, measured 
interstitial and residual plasma fractions were used and a tissue distribution flow was estimated 
in the model, allowing a detailed description of the biodistribution data. Overall, this is a 
relatively simple PBPK modelling approach compared to many of the more detailed previously 
published PBPK models (e.g., (Ferl et al., 2005; Garg & Balthasar, 2007; Urva et al., 2010; Chen 
& Balthasar, 2012). It is worthwhile noting, however, our intention here to keep the model 
complexity rather low while permitting for a realistic prediction of the biophase concentration 
within in the different tissues. Therefore, and to avoid unnecessary complexity and parameter 
identifiability issues, we omitted processes where experimental data were lacking. We 
acknowledge, though, that depending on the research question, more detailed model structures, 
including additional processes, could be necessary (e.g., target binding, FcRn receptors, 
endosomal compartment, etc.). It is of interest that the herein presented data and parameter 
values offer essential information on tissue composition, antibody target-site distribution and 
parameter identifiability independently from the model structure and could be integrated into 
other PBPK models. 
In conclusion, we have provided novel data essential for PBPK modelling of monoclonal 
antibodies. To our knowledge, this is the first time that a PBPK model has been used to directly 
describe measured tissue interstitial PK for monoclonal antibodies. The measured input 
parameters, their direct integration and the critical evaluation of the measured and previously 
used values, as well as the underlying experimental methods, are vital for a more realistic 
interpretation of tissue PK data for antibodies. This allows us to model antibody tissue 
distribution and removal in a more tissue-specific way based on physiological rationale. We 
show that the use of residual plasma correction factors based on red blood cell distribution can 




demonstrate by direct measurements and model-based data interpretation that in most tissues, 
high interstitial concentrations can be achieved for antibodies that contradicts the still-prevailing 
view that antibody distribution to the tissue interstitial space is quite limited and low 
concentrations are expected. These findings also supply new insights with a potential impact on 
the development of IgG therapeutics. They show that the use of total tissue concentrations of 
antibodies can be highly misleading and does not reflect how much of the therapeutic antibody 
potentially reaches its target in the interstitial space. Correlating this concentration to a 
therapeutic effect could therefore bias the estimated potency of the respective antibody drug, and 
potential in vitro - in vivo correlation or upfront predictions of drug effect would be biased. The 
model developed herein offers a more precise prediction of the distribution of IgG antibodies to 
the interstitial space of individual tissues. These predicted target-site concentrations might be 
utilised to better assess the PKPD relationship and potency of antibody therapeutics. This 
knowledge could then potentially be further employed to more accurately predict expected PK 
and the therapeutic effect of IgG antibody agents upfront, also following alternative dosing 
schedules.  
We believe that our findings are broadly applicable for IgG monoclonal antibodies which 
currently are the primary isotype for therapeutic antibodies. However, we recognise that 
differences in physicochemical properties, e.g., hydrodynamic radius or charge, for other Ig 
isotypes or engineered antibodies might affect certain distribution properties of protein 
therapeutics (e.g., passage through the endothelial layer or exclusion volume in the interstitial 
space). Investigating the impact of such factors on specific PK parameters during future studies, 
specifically combining experiments with PBPK modelling, could ultimately be a valuable next 
step to improve PBPK modelling for antibody therapeutics. 
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Table 1: Subcompartmental volume fractions in tissues  
Tissue Adipose Bone Brain Gut Heart Kidney Liver Lung Muscle Skin Spleen 
fECV 0.101 0.176 - 0.197 0.210 - 0.333 0.364 0.137 0.448 0.184 
CV (%) 42.9 15.0 - 14.9 19.3 - 15.6 11.7 25.3 7.9 20.8 
fResPla 0.007 0.043 0.012 0.022 0.086 0.108 0.094 0.137 0.009 0.017 0.065 
CV (%) 47.8 14.1 22.7 27.8 19.2 10.9 15.7 16.7 15.5 30.6 26.0 
fVint 0.093 0.133 - 0.175 0.123 - 0.239 0.227 0.127 0.431 0.119 
CV (%) 46.2 20.3 - 17.1 35.8 - 22.6 21.1 27.6 8.4 35.3 
Table 1: Measured extracellular (fECV), residual plasma volume fractions (fResPla) and derived interstitial volume fractions (fVint) in 
mL/g tissue presented as mean and coefficient of variation (CV) for all 11 tissues.  



























0.100 2.525 0.133 13.3 
Brain 0.012 
(± 1.7e-5) 














0.005 0.135 0.123 31.8 
Kidney 0.101 
(± 1.3e-4) 
- - 0.060 0.470 - 59.6 
Liver 0.082 
(± 1.1e-4) 
























0.250 4.475 0.430 24.3 
Spleen 0.061 
(± 8.7e-5) 
- - 0.028 0.125 - 7.1 
Other parameters 
Syst. Vpla  
(mL)b 





















Table 2: Summary of the parameter values used and estimated for the PBPK modelling approach. (a) Estimated but restricted to the 
range of the measured values ± 20%; (b) Estimated values; (c) Fixed values based on (Eigenmann et al., 2017), note: bone and 
adipose assumed; (d) Relative values derived from Shah et al. (Shah & Betts, 2012) and scaled to a 25g mouse; (e) Fixed to 
measured values; f) estimated but restricted to the range of the measured values ± 30%. The 95% confidence intervals (CI) for the 
parameters estimates are defined in brackets below the estimated value with the upper and lower bound of the 95% CI being 
defined as the estimate + or – the value in the bracket, respectively. A narrow confidence interval indicates a precise estimation of 
the respective model parameters. Definitions: residual plasma fraction (fResPla), tissue distribution (Tissue dist.), fractional 
contribution to total systemic clearance (Frct.CL), interstitial volume fraction (fVint), systemic plasma volume (Syst. Vpla), total 
systemic clearance (Total CL), plasma cardiac output (CO plasma), accessible volume fraction in interstitial space (Frct. access.) 
and residual plasma fraction in tissue centrifugate (fResPla cent.). 
Figure legends 
Figure 1: a) Schematic model structure. Solid arrows depict the blood flows and the dashed arrows indicate leaving of the tissue 
interstitial space (grey) indicates the lymph flow (where estimable). The tissues are modelled depending on their vasculature and 
are depicted again separately in the sub-plots, including the respective tissue-specific model parameters; (b) Tissues with 
continuous capillaries (green); (c) Tissues with capillaries largely impenetrable for IgGs, i.e., brain and kidney (orange); and (d) 
Tissues discontinuous capillaries (blue). The tissue-specific model parameters are: arterial plasma flow (Qtis), lymph flow (Ltis), 
intrinsic clearances (CLtis), residual plasma volume (Vvtis) and the interstitial volume (Vitis). The venous blood flow is defined by (Qtis-
Ltis).  
Figure 2: Individual (open circles) and mean (solid lines) anti-IL17 IgG total concentrations in plasma and the 11 tissues harvested 
at 10 time points over 15 days. Each profile is a composite profile, i.e., each individual data point was measured in a different 
mouse. Also shown in each sub-plot is a detailed zoom-in plot of the initial phase (0.6 d) of the concentration-time experiment.   
Figure 3: Concentration of anti-IL17 IgG in the isolated fluid of the muscle and skin as a function of time after injection. Open circles 
indicate individual measurements (three mice per time point) and the solid curve is the mean profile. A detailed zoom-in plot of the 
initial phase (0.6 d) of the concentration-time experiment is found in both subplots. 
Figure 4: a) Measured 51Cr-EDTA spaces for different tissues in six mice. Individual volumes are reported per gram wet weight and 
mean and standard deviation are shown for each tissue; and b) Depiction of residual plasma fractions remaining in the tissues after 
harvesting. Individual measurement data, their mean and standard deviation are given for each tissue.  




plasma assessed as 125I-albumin distribution volume (solid red curve) and anti-IL17 IgG distribution volume (dashed red curve) after 
5 and 10 min of circulation time, respectively. The blue-shaded area shows anticipated extravascular antibody concentration after 
accounting for the drug content in the calculated tracer distribution spaces. The size of the blue-shaded area is defined by the 
difference in the volume fraction assessed by 125I-albumin distribution after 5 min and 125I-anti-IL17 IgG distribution after 10min. 
Figure 6: Measured total tissue PK profiles (solid profile with mean and standard deviation) corrected for amount of drug in residual 
plasma assessed as 125I-albumin distribution volume (solid red curve) and anti-IL17 IgG distribution volume (dashed red curve) after 
5 and 10 min of circulation time respectively. In these tissues no or very low extravascular tissue concentrations were expected after 
accounting for the drug in the assessed tracer spaces (blue-shaded area). The size of the blue-shaded area is defined by the 
difference in the volume fraction assessed by 125I-albumin distribution after 5min and 125I-anti-IL17 IgG distribution after 10 min. 
Figure 7: Measured removal rates in skin (filled) and muscle (open) for BSA, normal IgG antibody and FcRn non-binding IgG, 
respectively. Washout rates (in 1/h) were 0.32±0.06, 0.31±0.09 and 0.36±0.05 in skin and 0.13±0.03, 0.11±0.05 and 0.14±0.04 in 
muscle for BSA, IgG and FcRn non-binding IgG, respectively. 
Figure 8: Model description of the biodistribution data. The model prediction is shown as the black solid line. The fitted mean PK 
data are represented by the open circles. Amount of drug in the residual plasma of the tissues is depicted in red, in interstitial fluid 
with the in blue-dashed lines and where not distinguishable in green. 
Figure 9: Overview of the sensitivities of the model outputs (y-axis) on perturbations in the individual parameters (x-axis). The 
sensitivity was averaged over the entire simulated time-course of 360 h. Yellow indicates high- and dark blue low impact of changes 
in the parameters on the respective model output. The colour-code is presented on the scale on the right side of the figure. 
Figure 10: Total tissue PK in tissues corrected for amount of drug in residual plasma in harvested tissues. Residual plasma volumes 
are determined based on either red blood cell distribution volumes reported by Garg (2007; green-dashed) and Boswell (2014; 
green-solid) and converted to plasma using a haematocrit value of 0.45 or by directly assessing the plasma space with labelled HSA 
(solid red) and IgG (dashed orange). It is clearly demonstrated that the red blood cell-based method leads systematically to lower 
correction and thus higher expected extravascular concentrations in tissues (grey-shaded area) than when directly assessed with 







Atis = Amount in tissue     Aitis = Amount in tissue interstitial space 
Avtis = Amount in tissue residual plasma  Ctis = Total tissue concentration 
Cinttis = Tissue interstitial concentration  CLintpla = Total systemic clearance 
fCLtis = Fractional contribution to clearance  Ltis = Tissue lymph flow  
Qtis = Tissue arterial plasma flow   Inflow = Antibody tissue distribution flow 
Vpla = Systemic plasma volume   Vtis = Total tissue volume  
Vitis = Tissue interstitial volume   Vvtis = Tissue residual plasma volume 
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𝑉𝑝𝑙𝑎











 =  
𝐼𝑛𝑓𝑙𝑜𝑤𝑔𝑢𝑡 × 𝐴𝑣𝑔𝑢𝑡
𝑉𝑣𝑔𝑢𝑡












 −  
𝐼𝑛𝑓𝑙𝑜𝑤ℎ𝑒𝑎 × 𝐴𝑣ℎ𝑒𝑎
𝑉𝑣ℎ𝑒𝑎











 =  
𝐼𝑛𝑓𝑙𝑜𝑤ℎ𝑒𝑎 × 𝐴𝑣ℎ𝑒𝑎
𝑉𝑣ℎ𝑒𝑎








 =  
𝑄𝑘𝑖𝑑 × 𝐴𝑝𝑙𝑎
𝑉𝑝𝑙𝑎
 −  
𝑄𝑘𝑖𝑑 × 𝐴𝑣𝑘𝑖𝑑
𝑉𝑣𝑘𝑖𝑑
 −  
 𝐴𝑣𝑘𝑖𝑑
𝑉𝑣𝑘𝑖𝑑





















 −  
 𝐴𝑣𝑙𝑖𝑣
𝑉𝑑𝑙𝑖𝑣


































 +  
𝑄𝑏𝑟𝑎 × 𝐴𝑣𝑏𝑟𝑎
𝑉𝑣𝑏𝑟𝑎
 −  
 𝐴𝑣𝑙𝑢𝑛
𝑉𝑣𝑙𝑢𝑛















 =  
𝑄𝑚𝑢𝑠 × 𝐴𝑝𝑙𝑎
𝑉𝑝𝑙𝑎
 −  
𝐼𝑛𝑓𝑙𝑜𝑤𝑚𝑢𝑠 × 𝐴𝑣𝑚𝑢𝑠
𝑉𝑣𝑚𝑢𝑠











 =  
𝐼𝑛𝑓𝑙𝑜𝑤𝑚𝑢𝑠 × 𝐴𝑣𝑚𝑢𝑠
𝑉𝑣𝑚𝑢𝑠












 =  
𝐼𝑛𝑓𝑙𝑜𝑤𝑠𝑘𝑖 × 𝐴𝑣𝑠𝑘𝑖
𝑉𝑣𝑠𝑘𝑖







 =  
𝑄𝑠𝑘𝑖 × 𝐴𝑝𝑙𝑎
𝑉𝑝𝑙𝑎
 −  
𝐼𝑛𝑓𝑙𝑜𝑤𝑠𝑘𝑖 × 𝐴𝑣𝑠𝑘𝑖
𝑉𝑣𝑠𝑘𝑖
 −  
(𝑄𝑠𝑘𝑖−𝐿𝑠𝑘𝑖) × 𝐴𝑣𝑠𝑘𝑖
𝑉𝑣𝑠𝑘𝑖









 =  
𝑄𝑠𝑝𝑙 × 𝐴𝑝𝑙𝑎
𝑉𝑝𝑙𝑎
 −  
𝑄𝑠𝑝𝑙 × 𝐴𝑠𝑝𝑙
𝑉𝑑𝑠𝑝𝑙
 −  
 𝐴𝑠𝑝𝑙
𝑉𝑑𝑠𝑝𝑙
× 𝐶𝐿𝑖𝑛𝑡𝑝𝑙𝑎 × 𝑓𝐶𝐿𝑠𝑝𝑙  
 
Model definitions 
𝐶𝑝𝑙𝑎  =  
𝐴𝑝𝑙𝑎
𝑉𝑝𝑙𝑎
   
 
𝐶𝑡𝑖𝑠 =  
𝐴𝑖𝑡𝑖𝑠 + 𝐴𝑣𝑡𝑖𝑠
𝑉𝑡𝑖𝑠
 
 
𝐶𝑖𝑛𝑡𝑠𝑘𝑖  =
𝐴𝑖𝑠𝑘𝑖 + 𝐴𝑝𝑠𝑘𝑖
𝑉𝑣𝑠𝑘𝑖
× 𝑓𝑉𝑝𝑙𝑎𝑐𝑒𝑛𝑡𝑠𝑘𝑖
𝑉𝑖𝑠𝑘𝑖 × 𝑓𝑎𝑐𝑐𝑒𝑠𝑠𝑠𝑘𝑖)
  
 
 
34 
 
𝐶𝑖𝑛𝑡𝑚𝑢𝑠  =
𝐴𝑖𝑚𝑢𝑠 + 𝐴𝑝𝑚𝑢𝑠
𝑉𝑣𝑚𝑢𝑠
× 𝑓𝑉𝑝𝑙𝑎𝑐𝑒𝑛𝑡𝑚𝑢𝑠
𝑉𝑖𝑚𝑢𝑠 × 𝑓𝑎𝑐𝑐𝑒𝑠𝑠𝑚𝑢𝑠)
 
  
 
35 
 
 
36 
 
 
37 
 
 
38 
 
 
39 
 
 
40 
 
 
41 
 
 
42 
 
 
43 
 
 
